Data on the use of MaxCyte electroporation to transfect insect cells without baculovirus to be presented.


Gaithersburg, MD, March 20, 2014  – MaxCyte®, Inc., the pioneer in scalable, high-performance cell transfection systems, will present data in both a scientific talk and a poster during the World Vaccine Congress on March 24-26, 2014, that demonstrates the use of flow electroporation for the rapid and scalable transfection of cells in vaccine development. The data will show that MaxCyte’s technology enables the manufacture of multiple-gram quantities of recombinant protein antigens, virus-like particles (VLPs), viral vectors, or viruses for tens of thousands of doses in a single process run.


The MaxCyte STX® Scalable Transfection System meets the need for transient gene expression that is quick, consistent, scalable, and cGMP compliant. With the ability to transfect 5E5 cells to 2E10 cells in a single run, the platform is a fully scalable means of transiently transfecting adherent and suspension cell lines commonly used during vaccine development and production such as CHO, HEK, and insect cells. The MaxCyte VLX® Large Scale Transfection System can transfect up to 2E11 cells with no additional scale-up development studies. Thus, both the STX and the VLX can provide the speed and protein quantities necessary when facing pandemic, biodefense, or even seasonal influenza needs.


“The MaxCyte flow electroporation process transfects insect cells directly without the use of baculovirus, with a timeline of just a few days from plasmid to protein,” says Dr. Karen Donato, Executive Vice President of Global Business Development and Marketing at MaxCyte. “The simplicity of the process can enable regional ‘vaccine in a box’ production facilities.”


Dr. James Brady, Director of Technical Applications, will present data on the use of MaxCyte’s unique flow electroporation technology to rapidly transfect multiple cell types in vaccine research and development in a scientific talk entitled, “Streamlining Vaccine Development and Production: Scalable Transient Transfection of Relevant Cell Types Using Flow Electroporation” on Tuesday, March 25 at 3:15 PM. MaxCyte also will present a scientific poster entitled “Rapid Production of Proteins, Antibodies, & Vaccines Using Scalable Flow Electroporation: From Plasmid to Protein in Days” with data demonstrating the ability of the MaxCyte platform to achieve high transfection performance in the production of antibodies, VLPs, and a lentiviral vector. Data also will be presented on high-efficiency transfection of cells commonly used in protein production including CHO, HEK293, and insect cells.


“Although a variety of transient transfection methods are available, most do not meet the requirements of scalability, consistency, and cell type flexibility,” says Douglas Doerfler, President and CEO of MaxCyte. “MaxCyte’s proprietary flow electroporation technology reproducibly transfects a broad range of adherent and suspension cell types with high cell viabilities and transfection efficiencies, which is exactly what is needed in vaccine research and development.


About MaxCyte

MaxCyte specializes in cell modification technologies to enable the discovery, development, manufacturing, and delivery of innovative therapeutic products. Drawing on its cell therapy expertise, MaxCyte designed a portfolio of products including the MaxCyte STX® Scalable Transfection System and MaxCyte VLX® Large Scale Transfection System, ideal tools for use in drug discovery research and screening and protein production environments. These products provide for the rapid development and consistent production of billions of (co)transfected primary cells, stem cells, and cell lines for protein and antibody production, for rapid response vaccine development, and for cell-based assays with comparable results and Seamless Scalability™ from the bench to HTS and pilot and production scale.

For more information visit /